Article
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
JAMA oncology - 1 Mar 2018
Zaanan Aziz, Shi Qian, Taieb Julien, Alberts Steven R, Meyers Jeffrey P, Smyrk Thomas C, Julie Catherine, Zawadi Ayman, Tabernero Josep, Mini Enrico, Goldberg Richard M, Folprecht Gunnar, Van Laethem Jean Luc, Le Malicot Karine, Sargent Daniel J, Laurent-Puig Pierre, Sinicrope Frank A
Abstract excerpt
IMPORTANCE: The prognostic impact of DNA mismatch repair (MMR) status in stage III colon cancer patients receiving FOLFOX (folinic acid, fluorouracil, and oxaliplatin) adjuvant chemotherapy remains controversial. OBJECTIVE: To determine the association of MMR status with disease-free survival (DFS) in patients with stage III colon cancer treated with FOLFOX. DESIGN, SETTING, AND PARTICIPANTS: The evaluated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.